



OPEN

# Novel common variants and susceptible haplotype for exfoliation glaucoma specific to Asian population

SUBJECT AREAS:  
GENOME-WIDE  
ASSOCIATION STUDIES  
GENETIC TESTING

Received  
13 November 2013

Accepted  
28 May 2014

Published  
18 June 2014

Correspondence and requests for materials should be addressed to S.K. (shigeruk@koto.kpu-m.ac.jp) or K.T. (tashiro@koto.kpu-m.ac.jp)

\* These authors contributed equally to this work.

Masakazu Nakano<sup>1\*</sup>, Yoko Ikeda<sup>2\*</sup>, Yuichi Tokuda<sup>1\*</sup>, Masahiro Fuwa<sup>1,3</sup>, Morio Ueno<sup>2</sup>, Kojiro Imai<sup>2</sup>, Ryuichi Sato<sup>1</sup>, Natsue Omi<sup>1</sup>, Hiroko Adachi<sup>1</sup>, Masaaki Kageyama<sup>3</sup>, Kazuhiko Mori<sup>2</sup>, Shigeru Kinoshita<sup>2</sup> & Kei Tashiro<sup>1</sup>

<sup>1</sup>Department of Genomic Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan, <sup>2</sup>Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan, <sup>3</sup>Research and Development Center, Santen Pharmaceutical Co. Ltd., Nara, Japan.

The common variants in lysyl oxidase-like 1 gene (*LOXLI*) are associated with exfoliation glaucoma (XFG) patients developed through exfoliation syndrome (XFS). However, the risk allele of a variant in *LOXLI* has been found to be inverted between Asian and Caucasian populations. Therefore, we newly performed a genome-wide association study using 201 XFS/XFG and 697 controls in Japanese, and identified 34 genome-wide significant single-nucleotide polymorphisms (SNPs) distributing in not only *LOXLI* but also *TBC1D21* and *PML* at the 15q24.1 locus. These SNPs were confirmed by an independent population consisted of 121 XFS/XFG and 263 controls in Japanese. Moreover, further analyses revealed a unique haplotype structure only from the combination of *TBC1D21* and *LOXLI* variants showing a high XFS/XFG susceptibility specific for the Asian population. Although there still should be other gene(s) in the other region(s) contributing to the disease process, these results suggested that the combination of newly discovered variants in these genes might be useful for precise XFG risk assessment, as well as for elucidating the molecular mechanism of XFG pathogenesis through XFS.

Glaucoma is one of the leading causes of irreversible blindness worldwide<sup>1</sup>. It is a complex age-related disorder consisting of heterogeneous subtypes that share common features for the development of the disease, i.e., progressive loss of retinal ganglion cells and optic nerve axons that result in visual field defects<sup>2</sup>. Therefore, it is important to investigate each distinct type of glaucoma in order to elucidate the different molecular pathways that lead to the common optic-nerve degeneration.

Exfoliation glaucoma (XFG) is categorized as secondary open-angle glaucoma and reportedly develops from exfoliation syndrome (XFS), as manifested by an observation of abnormal fibrillar deposits (known as pseudoexfoliation (PEX)) on the lens and iris epithelium<sup>3</sup>. In general, XFG has a worse prognosis than primary open-angle glaucoma (POAG), the major type of glaucoma, as it is often observed in patients as elevated intraocular pressure (IOP) combined with severe damage of visual function at the time of initial presentation due to the asymptomatic nature of glaucoma. Moreover, according to the findings reported in the Tajima Study<sup>4</sup>, a robust epidemiology study conducted in Japan, XFG accounts for 0.8% of the 5.0% of all types of glaucoma observed in Japanese people over 40 years of age, and the prevalence of XFG increases with advancing age. Consequently, it would be of enormous benefit if the predisposing genetic factors of XFG could be used to predict the risk of developing the disease prior to onset in order to stop, or at least hinder, the irreversible progression toward blindness by initiating early medical intervention.

In 2007, Thorleifsson *et al.* reported a genome-wide association study (GWAS) using the populations from Iceland and Sweden, and described that one intronic variant and two nonsynonymous coding variants of lysyl oxidase-like 1 gene (*LOXLI*) confer the risk of developing XFG, possibly through XFS<sup>5</sup>. From the functional point of view, the involvement of *LOXLI* in XFG pathogenesis is quite rational, because *LOXLI* plays an indispensable role in elastic fiber homeostasis and maintaining the structures of the trabecular meshwork, the tissue that determines the IOP level in the eye<sup>6</sup>. However, *LOXLI*, in and of itself, fails to sufficiently explain the complex mechanism of the disease progression of XFG through XFS. This observation is also supported from the point of view of genetics, as many replication studies using populations derived from different genetic backgrounds



(Caucasians from the US<sup>7-9</sup> and Europe<sup>10,11</sup>, Asians from Japan<sup>12-16</sup> and China<sup>17,18</sup>, and Africans from South Africa<sup>19</sup>) have succeeded in replicating the association of the *LOXL1* variants, although the allele frequency of the variants varied among the ethnicities. In fact, the risk allele of one of the exonic variants (rs1048661) has been found to be inverted between Japanese<sup>12</sup> and Nordic populations<sup>5</sup>. Consequently, it is wise to investigate other modifying or causative variants in genes other than *LOXL1* by performing a GWAS using a non-Caucasian population in order to identify variants that are determining the different etiology of XFS onset and its progression to XFG among the ethnicities.


In this present study, we conducted a GWAS and replication study using two independent populations of Japanese case-control subjects in an attempt to identify new variants associated with XFS/XFG. As a result, we identified a cluster of genome-wide significant SNPs only from the chromosome 15q24.1, which is well known as a locus including *LOXL1*<sup>5</sup>. However, the genome-wide significant SNPs were distributed in not only *LOXL1*, but also in the two adjacent genes, *TBC1D21* and *PML*, without being in significant linkage disequilibrium (LD). We also identified a suggestive association only between *TBC1D21* and *LOXL1* variants by a conditional analysis, and revealed a unique haplotype structure of the variants derived from these two genes in our study population. Together with the accumulating knowledge of *LOXL1*-XFS/XFG relationships, the variants and genes newly discovered in this study would help to provide a better prediction of XFG risk assessment, as well as to elucidate the molecular mechanism of XFG pathogenesis through XFS.

## Results

**GWAS for XFS/XFG.** The samples used in this study are summarized in Table 1. In order to perform GWAS, we first selected the XFS/XFG subjects based on our strict diagnosis criteria, and then obtained the genotype data. We performed a GWAS using a population consisting of 201 XFS/XFG patients and 697 healthy controls (Table 1). In total, 652,792 SNPs that passed the quality controls (QC) were used for the association study (Figure 1A). According to the quantile-quantile (Q-Q) plot (Supplementary Material, Figure S1), the genomic inflation factor ( $\lambda$ ) showed 1.020, suggesting that the population substructure should not have any substantial effects on the association analysis. Under those conditions, we observed a strong association signal from a locus on chromosome 15 (Figure 2A). In fact, we obtained 34 genome-wide significant SNPs (Supplementary Material, Table S1) that passed the Bonferroni correction threshold ( $0.05/652,792 = 7.66 \times 10^{-8}$ ) on chromosome 15q24.1 (Figure 2A). Surprisingly, these significant SNPs were found to be broadly distributed in not only *LOXL1*, but also the adjacent two genes, *TBC1D21* and *PML*. The significance for this region was also confirmed by an imputation analysis (Figure 2B). According to the LD plots (Supplementary Material, Figure S2A), the

Table 1   Sample Information					
Study	Group	Subgroup	n	Age	F/M
GWAS	XFS/XFG <sup>a</sup>	Total	201	74.3 ± 8.9	0.9
		XFG	162	75.3 ± 8.5	0.8
		XFG with other glaucoma	21	72.3 ± 10.5	0.9
		XFS	18	66.8 ± 6.6	3.5
Replication	XFS/XFG <sup>b</sup>	Total	697	58.5 ± 13.4	1.9
		XFG	121	74.7 ± 8.6	1.0
		XFG with other glaucoma	103	75.8 ± 7.9	0.8
		XFS	18	68.4 ± 9.8	2.6
	Control	Total	263	48.6 ± 14.8	1.5


<sup>a</sup>Ninety XFG and 2 XFG with other glaucoma samples are overlapped with our previous study<sup>12</sup>.  
<sup>b</sup>One XFG sample is overlapped with our previous study<sup>12</sup>.



**Figure 1 | Study design.** (A) First, a GWAS was performed and 652,792 SNPs were analyzed for 201 XFS/XFG patients and 697 controls. As a result, 34 genome-wide significant SNPs were obtained from the genes of *TBC1D21*, *LOXL1*, and *PML* at 15q24.1 locus. (B) Next, the GWAS results were replicated by analyzing 43 SNPs from the 15q24.1 locus by using an independent population of 121 XFS/XFG patients and 263 controls. (C) Finally, a meta-analysis was performed by combining the two data sets by use of the Mantel-Haenszel test. In addition, the pairs of significant SNPs were assessed by conditional and haplotype analyses. The result suggested the susceptible haplotype might exist for XFS/XFG from *TBC1D21* and *LOXL1* variants.

SNPs in each gene seemed to be derived from 3 distinct LD blocks, which was also confirmed by the LD values using 34 genome-wide significant SNPs (Supplementary Material, Table S2).

**Replication study.** Next, we attempted to replicate the GWAS results by analyzing an independent Japanese population consisting of 121 XFS/XFG patients and 263 controls (Table 1). We assessed a total of 43 SNPs at 15q24.1 locus, including 34 genome-wide significant SNPs from our GWAS results and 2 nonsynonymous coding SNPs (cSNPs) (rs1048661 and rs3825942) in exon 1 of *LOXL1* that reportedly are strongly associated with XFS/XFG<sup>5</sup>. As a result, almost every genome-wide significant SNP, except 1 SNP (rs723434), passed the Bonferroni correction threshold in the replication study ( $0.05/43 = 1.16 \times 10^{-3}$ ) (Supplementary Material, Figure S2B and Table S3), confirming the association results obtained by GWAS. We also confirmed the association result of the reported 2 cSNPs in *LOXL1* using our Japanese population, of which the risk allele of rs1048661 was indeed inverted from the reported result with Caucasian. When the combined *P* values of GWAS and the replication study were calculated by use of the Mantel-Haenszel test<sup>20</sup>, the level of significance of almost every SNP increased. In fact, rs893818, which was the most significant SNP in intron 1 of *LOXL1*, reached to  $P = 8.21 \times 10^{-84}$  (Supplementary Material, Figures S2C and S2D, Table S4). The rs893818 SNP was clearly independent from the SNPs in *TBC1D21* and *PML* as in reference to the LD values calculated by applying the whole samples used in this study (Supplementary Material, Table S2). Moreover, the LD blocks based on the whole samples demonstrated that *LOXL1*, *TBC1D21*, and *PML* were in 3 distinct LD blocks, suggesting that the variants from different genes were independently contributing to the disease (Supplementary Material, Figures S2E and S2F).



**Figure 2 | Association results.** (A) The SNPs with a strong association signal from the GWAS result appeared to exist as a cluster on chromosome 15 (red arrow). Horizontal dotted line represents Bonferroni correction threshold ( $P < 7.66 \times 10^{-8}$ ). (B) Because the genome-wide significant SNPs were intensively identified on the 15q24.1 locus, we also imputed the SNPs across the locus and plotted against the positions based on the NCBI Build 36 coordinates. The LD value of  $r^2$  is referred to the most significant SNP (rs893818) in the GWAS. The cSNP (rs16958445) and two genes (*TBC1D21* and *LOXL1*) used in the conditional and haplotype association analyses are highlighted by red. The genetic recombination rates (cM/Mb) estimated by HapMap Project<sup>31</sup> in Release 22 are indicated by the thin blue line.

**Meta-analysis of two studies.** We then performed a conditional analysis for 34 genome-wide significant SNPs on the basis of rs893818 according to our GWAS result. Overall, it turned out that the effect of rs893818 was very strong, while the variants in *TBC1D21* and *PML* were generally weak, although we found a suggestive signal ( $P = 0.027$ ) from a nonsynonymous variant in exon 4 of *TBC1D21* (rs16958445) (Supplementary Material, Table S5). These two SNPs were considered to be truly associated with XFS/XFG because there were no confounding factors such as age and gender (Supplementary Material, Table S6). Consequently, we obtained 3 susceptible cSNPs, including 2 reported cSNPs in *LOXL1*, showing a weak correlation ( $r^2 < 0.2$ ) to each other (Supplementary Material, Figures S3).

Therefore, we then evaluated the combinational effect of 3 cSNPs (rs16958445 from *TBC1D21*, and rs1048661 and rs3825942 from *LOXL1*) in order to analyze the susceptibility to XFS/XFG by performing a haplotypic association analysis with the samples used in the replication study (Table 2). As a result, haplotype H6 (rs16958445: G, rs1048661: T, and rs3825942: G) was most significant for the association with XFS/XFG. Interestingly, haplotype H6 was more significant than haplotypes H3 and H4, including the significant haplotype (rs1048661: G and rs3825942: G) in the *LOXL1* for the Caucasian population<sup>5</sup>. In addition, according to the dbSNP database, rs16958445 in *TBC1D21* was found to be monomorphic for the G allele in Caucasian and



Table 2 | Results of Haplotype Association Analysis

Haplotypes	SNP alleles <sup>a</sup>	Freq. in XFS/XFG	Freq. in controls	Chi-square	P-values <sup>b</sup>
H1	OMNIBUS	NA	NA	122.4	$9.57 \times 10^{-25}$
H2	GGA	0.0039	0.1294	31.9	$1.62 \times 10^{-8}$
H3	GTA	0.0043	0.0407	7.7	0.0055
H4	AGG	0.0176	0.0835	12.2	0.0005
H5	GGG	0.0125	0.1517	33.4	$7.55 \times 10^{-9}$
H6	ATG	0.0319	0.0675	3.9	0.0471
H6	GTG	0.9297	0.5272	118.5	$1.33 \times 10^{-27}$

<sup>a</sup>Haplotypes were constructed with the SNPs in the following order: rs16958445, rs1048661, and rs3825942.

<sup>b</sup>P values were calculated by use of the 'hap-assoc' option of PLINK.

African populations. Consequently, we obtained a unique haplotype structure in this present study showing a high XFS/XFG susceptibility specific for the Asian population.

Taken together, the newly identified genes in 15q24.1 locus, together with the unique haplotype of *TBC1D21* and *LOX1L1* variants, could add some information to explain the molecular mechanism of XFS/XFG pathogenesis, which has been considered difficult to explain by *LOX1L1* alone.

## Discussion

In this study, we successfully obtained the genetic markers strongly associated with XFS/XFG patients by analyzing two independent Japanese populations totaling 1,282 subjects from GWAS and its replication study. As a result, we discovered the genome-wide significant variants in not only *LOX1L1*, but also 2 other genes, *TBC1D21* and *PML*, both of which are located on chromosome 15q24.1, which is well known as the “*LOX1L1* locus”<sup>5</sup>. We also found a suggestive combinational effect of the variants related to the XFS/XFG susceptibility only between *LOX1L1* and *TBC1D21*, which seemed to be specific to Asian population.

In the first reported GWAS for XFS/XFG, Thorleifsson *et al.* detected a strong association signal only in *LOX1L1* at the 15q24.1 locus from a Nordic population<sup>5</sup>. Their GWAS was carried out based on the genotype data generated by using the Infinium HumanHap300 BeadChip (Illumina, Inc., San Diego, California, USA) array, whereas we used the Genome-Wide Human SNP Array 6.0 (SNP 6.0; Affymetrix, Inc., Santa Clara, California, USA), in which the SNP coverage is more than three-fold. We precisely compared the probe disposition derived from each microarray as well as the association results from the two studies across the locus (Supplementary Material, Figure S4A and B). Although the number of QC-passed SNPs in the locus was different in the two studies depending on which microarrays and sample ethnicities were used, we were able to directly compare the results for some SNPs (Supplementary Material, Figure S4A; connected with green lines). As a result, a genome-wide significant SNP in *LOX1L1* was reproducible in both studies. However, the genome-wide significant SNPs in other genes at the 15q24.1 locus, especially in *TBC1D21* (Supplementary Figure S4B), obtained in our study using Japanese samples were not significant in the first reported GWAS using the Caucasian samples. Moreover, we found that 1 of the significant SNPs in *TBC1D21*, rs16958445, which together with 2 cSNPs in *LOX1L1* seemed to be contributing to the disease according to the results of the conditional analysis, was a monomorphic SNP in all of the HapMap populations other than Asian (see dbSNP in NCBI).

With regard to rs16958445, the non-risk allele “A” was a minor allele, whose frequency was about 0.144–0.157 or 0.166 in Japanese, according to the dbSNP or our control samples, respectively (Supplementary Material, Table S4). This meant that the contribution of rs16958445 to the XFS/XFG susceptibility might be limited for explaining the different susceptibility among the ethnicities. However, the results of the haplotype association analysis by 3

cSNPs (H6: GTG in Table 2) demonstrated that the significance was higher than that by use of only 2 cSNPs in *LOX1L1* (Supplementary Material, H4: TG in Table S7). In addition, the non-risk allele of rs16958445 decreased the significance of the major susceptible haplotype in Caucasians (Supplementary Material, H3: GG in Table S7). Taken all together, we concluded that the discrepancy of the results from the two studies was due to the different genetic backgrounds of the samples, and not due to practical reasons such as the microarray density.

The association results of *LOX1L1* variants found in the Nordic population has been extensively characterized in many other populations with different ethnic backgrounds. In particular, out of the three variants reported, two coding variants of rs1048661 (Arg141Leu) and rs3825942 (Gly153Asp) in exon 1 were mostly analyzed by the replication analysis<sup>21</sup> (Supplementary Material, Figure S5). Although both of the variants were found to be associated with the disease broadly beyond the ethnicities, the risk alleles of rs1048661 and rs3825942 were, intriguingly, inverted in Japanese<sup>12</sup>/Chinese<sup>18</sup> and South African<sup>19</sup> populations, respectively. The inverted genotypes of the risk alleles among different populations may be reflecting the different patterns of historical recombination between these SNPs and the unidentified causative variants. However, the one thing that is apparent is that the particular amino-acid changes in *LOX1L1* protein were not functionally sufficient enough to be the causative factor for the disease pathogenesis. Consequently, it would have been wise to investigate other modifying or causative variants in genes other than *LOX1L1*. Thus, we decided to perform a GWAS using our Japanese population in order to identify unique variants contributing to the onset of XFS and its progression to XFG.

To date, only a limited number of disease-associated variants identified by GWAS were applicable to the actual diagnosis in the clinic setting. Thus far, a case in point is the diagnosis that has been applied to predict the risk of age-related macular degeneration (AMD)<sup>22,23</sup>. In order to predict the prevalence and incidence of AMD, multiple risk models have been developed by incorporating both the genetic and environmental factors, resulting in a marked increase of the accuracy to discriminate risk and non-risk individuals<sup>24</sup>. However, in the case of XFS/XFG, the situation is completely different from that of AMD, due to the limited number of identified genetic factors as well as their characteristics. Although the prevalence of *LOX1L1* variants in affected patients is strikingly high (>80%), which means that the sensitivity is high, the prevalence of unaffected controls is also high enough (up to 88%) to render the specificity being low, indicating that the simple allelic testing of *LOX1L1* variants themselves cannot exclude the individuals who would not develop XFS/XFG<sup>21</sup>. Although the variants identified in this study seemed to possess a weaker effect on the disease than the *LOX1L1* variants have, we also discovered a unique haplotype specific for the Japanese population (Table 2). Combining the information of each allele and the haplotypes would help in developing a better diagnosis to predict XFS/XFG risk by the genetic testing of these variants.





Since XFS is characterized by clinically visible abnormal fibrillar deposits (i.e., PEX), progressive accumulation of those deposits have been considered to be a trigger of developing glaucoma by increasing the outflow resistance of the trabecular meshwork, resulting in the continuous elevation of IOP<sup>3</sup>. The *LOXL1* protein, which catalyzes the formation of elastin fibers and contributes to the trabecular meshwork structures, is thus probably involved in the XFS/XFG pathogenesis<sup>6</sup>. However, the exonic variants in *LOXL1* fail to sufficiently explain the complex mechanism of the disease (e.g., as if they were affecting the quality (amino-acid changes) and/or quantity (expression level) of *LOXL1* protein) due to the differences in allelic distribution among different genetic backgrounds and the high prevalence of the variants in the healthy population<sup>21</sup>.

According to our GWAS result, the significant variants for XFS/XFG other than the *LOXL1* variants were newly discovered from *TBC1D21* and *PML* genes (Figure 2B, Supplementary Material, Figure S2). In fact, the *TBC1D21* gene, which belongs to the TBC1 domain family, was suggested to be related to *LOXL1* by haplotype association analysis (Table 2). The TBC (Tre-2/Bub2/Cdc16) domain consists of approximately 200 amino acids and is considered to function as a GTPase activator of Rab proteins. However, the functional details of more than 40 members of the protein families in humans and mice, including *TBC1D21*, have to date not been well investigated<sup>25</sup>. Although there are few functional analyses of the gene, our RT-PCR analysis revealed that *TBC1D21* is expressed in the human retina (Supplementary Material, Figure S6). When we compared the sequence conservation of the variant (rs16958445) among several species, we found that the variant was conserved within primates (Supplementary Material, Figure S7). We also performed *in silico* prediction in order to evaluate the influence of amino acid change in rs16958445 by means of SIFT<sup>26</sup> and PolyPhen-2<sup>27</sup>, and programs predicted as “TOLERATED” and “benign”, respectively. The results suggested that the amino acid change in rs16958445 does not affect the function of *TBC1D21* protein. Consequently, further functional investigation is necessary to elucidate whether or not *TBC1D21* involves in the disease etiology of XFS/XFG.

On the other hand, *PML* is functionally well characterized and would be a good target for analyzing the relationship to XFS/XFG etiology, although the contribution to XFS/XFG susceptibility was considered to be marginal than *TBC1D21* and *LOXL1* based on our analysis. *PML* is a member of the tripartite motif (TRIM) family and famous for being involved in generating fusion protein as a result of chromosomal translocation with the retinoic acid receptor alpha gene, which is often associated with acute promyelocytic leukemia<sup>28</sup>. The original function of *PML* protein is to form a nuclear body, which carries several components, such as pRB, p53, CBP, elf-4, Daxx, SUMO-1, etc<sup>29</sup>. Therefore, if the variants in *PML* cause inappropriate formation of the nuclear body, broad biological functions would be affected, including transcriptional regulation, initiation of translation, and sumoylation, which could associate with the elastic microfibrilopathy. In fact, our RT-PCR analysis shows that *PML* is expressed in the human retina (Supplementary Material, Figure S6). Consequently, we consider that it would be interesting to further investigate the involvement of *PML* in the XFS/XFG pathogenesis.

Although we succeeded in obtaining some new variants and genes associated with XFS/XFG, it should be noted that there must be other gene(s) in other region(s) contributing to the disease in order to explain the complex mechanism of XFS/XFG pathogenesis. Moreover, under the current GWAS condition, we are unable to verify whether or not the variants were specifically related to the mechanism for the progression to glaucoma from XFS. Since there are patients who possess PEX, but never develop glaucoma, other factors must be involved in determining whether or not XFS patients develop glaucoma. Together with the variants/genes identified in this study and the accumulated knowledge of *LOXL1*, the identification of the remaining variants as well as the variants specific for XFS

patients without glaucoma could provide a complete set of genetic factors associated with XFS and XFG, which should be useful for their diagnostic tools as well as for revealing the molecular mechanism of their etiology.

## Methods

**Subjects.** All of the procedures in this study were performed in accordance with the tenets set forth in the Declaration of Helsinki and were approved by the Institutional Review Board of Kyoto Prefectural University of Medicine, Kyoto, Japan. Written informed consent was obtained from all XFS/XFG participants after receiving a detailed and thorough explanation of the study. Those participants were interviewed to determine their familial history of glaucoma and the medical histories of other ocular or general diseases. The Japanese volunteers were recruited between March 2005 and August 2012 at the University Hospital of Kyoto Prefectural University of Medicine in order to provide peripheral blood samples. The genotyping data of this current study for XFS/XFG patients and healthy volunteers was simultaneously obtained with the data of our previous study for POAG<sup>30</sup>. From the complete data set, XFS/XFG cases and controls suitable for this study were selectively chosen from the complete data set based on the following strict diagnosis: 1) all XFG patients were diagnosed by slit-lamp examination for the existence of exfoliation materials on the pupil and surface anterior lens capsule with open angle, 2) IOP higher than 21 mmHg, and 3) visual field defect according to the optic nerve appearance. The category “XFG with other glaucoma” group includes normal tension glaucoma or primary angle closure glaucoma with XFS. All of the patients and healthy volunteers were diagnosed by 3 ophthalmologists (Y.I., M.U., and K.M.) from a single institution. The demographics (i.e., subject age and male-to-female ratio) of all of the subjects used in this study are shown in Table 1. To examine the possible confounding effects of the age and gender of the subjects, correlations between the case and control samples were assessed by use of the Student’s *t* test or chi-square test (Table 1).

**SNP genotyping and quality control for the GWAS.** As described previously<sup>30</sup>, 906,600 SNPs were genotyped for 2,126 Japanese subjects including POAG patients, XFS/XFG patients, and healthy volunteers by Genome-Wide Human SNP Array 6.0 (Affymetrix), and strict QC was applied. For the GWAS, 203 XFS/XFG patients and 718 controls were initially selected from the total number of subjects based on the latest diagnosis. In order to exclude subjects within the population who were genetically related, identity-by-descent estimates were performed for all possible combinations by PLINK v1.07 (see URLs). As a result, 2 XFS/XFG patients and 21 controls who were assumed to be genetically related were excluded from the GWAS population. Ultimately, the population ended up with 201 XFS/XFG patients and 697 controls (Figure 1A and Table 1). Population stratification was examined by principal component analysis using EIGENSTRAT software v3.0 (see URLs). The four HapMap populations (CEU, YRI, JPT, and CHB) were simultaneously applied into EIGENSTRAT as the reference. The generated cluster plots indicated that the XFG and control population were genetically clustered within the JPT population, and there was no outlier sample (Supplementary Material, Figure S8). In order to extract high-quality autosomal SNP genotype data, the following QC filters were applied: (i) call rate per SNPs in each case and control samples  $\geq 95\%$ , respectively, (ii) minor allele frequency (MAF) in case and control samples  $\geq 1\%$ , and (iii) Hardy-Weinberg equilibrium (HWE) in control samples with a *P*-value  $\geq 0.001$ . Consequently, the remaining 652,792 SNPs were analyzed for the XFS/XFG GWAS (Figure 1A).

**Replication study.** For the replication study, an independent population of 384 samples consisting of 121 XFS/XFG patients and 263 controls was prepared (Table 1). Those samples were extensively checked in order to remove any familial relationships. In total, 41 SNPs were applied to the replication by referencing the GWAS results as follows: 34 SNPs that passed the Bonferroni’s correction in our GWAS and 7 SNPs which were selected to be useful for confirming the LD region of 15q24.1 locus. In addition, 2 cSNPs (rs1048661 and rs3825942) were assessed that have been reported by Thorleifsson *et al.*<sup>5</sup>, yet are not designed in SNP 6.0. Furthermore, 4 SNPs associated with POAG in our previous study<sup>30</sup> were included in this replication assay. In total, 47 SNPs were divided into each of the two groups of 30 and 17 SNPs per assay plate, respectively, according to the manufacturer’s recommendation, and genotyped simultaneously for 384 samples in each group by use of the MassARRAY iPLEX Genotyping system (Sequenom, Inc., San Diego, California, USA). All of the resulting call rates of these SNPs were over 90%.

**Meta-analysis.** A meta-analysis was performed for 41 SNPs, which were genotyped in both the GWAS and replication study, by use of the Mantel-Haenszel test<sup>20</sup>. Among these SNPs, rs2165241 and rs4243042 were found to be monomorphic for the XFS/XFG subjects used in the replication study (i.e., the risk allele frequency was 100%). Therefore, those 2 SNPs were excluded from the Mantel-Haenszel test. Genotype imputation for GWAS was performed using MACH ver. 1.0.16 software (see URLs). The genotype data of JPT and CHB in the HapMap Phase 2<sup>31</sup> (release #24) were applied as the reference for haplotyping. After the QC was applied for the imputation results (MAF  $\geq 0.01$  and *Rsq*  $\geq 0.7$ ), association analysis of the SNPs for XFS/XFG was performed by use of mach2dat ver. 1.1.9 software (Windows version). Conditional analysis was assessed for 34 genome-wide significant SNPs using the combined samples from the GWAS and the replication study (i.e., 322 XFS/XFG patients and 960 controls). Haplotype analysis was examined with the samples from the



replication study in order to assess the reported cSNPs in *LOXL1*. Both conditional and haplotype analyses were performed by use of the PLINK v1.07 whole genome association analysis toolset.

**Data management and statistical analysis.** In order to manage and analyze all of the genotype data, our in-house Genoika Server System<sup>30,32,33</sup> was used. The Genoika Server System comes with PLINK, R program with some packages, EIGENSTRAT, and Haploview (see URLs for the details of each software) built in, and all of the analyses were performed by use of this system. In addition, Microsoft Office Excel 2003 (Microsoft Corporation, Redmond, Washington, USA) was used for preparing the data sets and statistical analysis. The frequency of alleles in the case and control samples was compared by use of the basic allele test. The odds ratio (OR) and the upper and lower limit of the 95% confidence interval (CI) of each SNP were calculated for the allele possessing a higher frequency in the case samples than in the control samples. The HWE was evaluated by use of the chi-square test. A regional plot in Figure 2 was drawn by use of LocusZoom ver. 1.1 (see URLs) genetic analysis software. Q-Q plots were generated by ranking the observed values from minimum to maximum and plotting them against their expected chi-square values using the “snpStats” package ver. 1.10.0 in the R program (see URLs).

**URLs.** PLINK software v1.07, <http://pngu.mgh.harvard.edu/~purcell/plink/>; EIGENSTRAT software v3.0, [http://genetics.med.harvard.edu/reich/Reich\\_Lab/Welcome.html](http://genetics.med.harvard.edu/reich/Reich_Lab/Welcome.html); MACH ver. 1.0.16 and mach2dat ver. 1.1.9 softwares, <http://www.sph.umich.edu/csg/abecasis/MACH/index.html>; Haploview v4.2, <http://www.broadinstitute.org/scientific-community/science/programs/medical-and-population-genetics/haploview/haploview>; LocusZoom version 1.1, <http://csg.sph.umich.edu/locuszoom/>; R programs, <http://www.r-project.org/>; SIFT dbSNP DB (build 132), <http://sift.jcvi.org/>; PolyPhen-2 version 2.2.2 r398, <http://genetics.bwh.harvard.edu/pph2/>.

- Quigley, H. A. & Broman, A. T. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* **90**, 262–7 (2006).
- Kwon, Y. H., Fingert, J. H., Kuehn, M. H. & Alward, W. L. Primary open-angle glaucoma. *N Engl J Med* **360**, 1113–24 (2009).
- European Glaucoma Society. Terminology and guidelines for glaucoma, 3rd Edition. (Dogma, Savona, Italy, 2008).
- Iwase, A. *et al.* The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. *Ophthalmology* **111**, 1641–8 (2004).
- Thorleifsson, G. *et al.* Common sequence variants in the *LOXL1* gene confer susceptibility to exfoliation glaucoma. *Science* **317**, 1397–400 (2007).
- Schlötzer-Schrehardt, U. Molecular pathology of pseudoexfoliation syndrome/glaucoma--new insights from *LOXL1* gene associations. *Exp Eye Res* **88**, 776–85 (2009).
- Fingert, J. H. *et al.* *LOXL1* mutations are associated with exfoliation syndrome in patients from the midwestern United States. *Am J Ophthalmol* **144**, 974–975 (2007).
- Challa, P. *et al.* Analysis of *LOXL1* polymorphisms in a United States population with pseudoexfoliation glaucoma. *Mol Vis* **14**, 146–9 (2008).
- Fan, B. J. *et al.* DNA sequence variants in the *LOXL1* gene are associated with pseudoexfoliation glaucoma in a U.S. clinic-based population with broad ethnic diversity. *BMC Med Genet* **9**, 5 (2008).
- Pasutto, F. *et al.* Association of *LOXL1* common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. *Invest Ophthalmol Vis Sci* **49**, 1459–63 (2008).
- Mossbock, G. *et al.* Lysyl oxidase-like protein 1 (*LOXL1*) gene polymorphisms and exfoliation glaucoma in a Central European population. *Mol Vis* **14**, 857–61 (2008).
- Mori, K. *et al.* *LOXL1* genetic polymorphisms are associated with exfoliation glaucoma in the Japanese population. *Mol Vis* **14**, 1037–40 (2008).
- Hayashi, H., Gotoh, N., Ueda, Y., Nakanishi, H. & Yoshimura, N. Lysyl oxidase-like 1 polymorphisms and exfoliation syndrome in the Japanese population. *Am J Ophthalmol* **145**, 582–585 (2008).
- Ozaki, M. *et al.* Association of *LOXL1* gene polymorphisms with pseudoexfoliation in the Japanese. *Invest Ophthalmol Vis Sci* **49**, 3976–80 (2008).
- Mabuchi, F. *et al.* Lysyl oxidase-like 1 gene polymorphisms in Japanese patients with primary open angle glaucoma and exfoliation syndrome. *Mol Vis* **14**, 1303–8 (2008).
- Fuse, N. *et al.* Evaluation of *LOXL1* polymorphisms in eyes with exfoliation glaucoma in Japanese. *Mol Vis* **14**, 1338–43 (2008).
- Lee, K. Y. *et al.* Association of *LOXL1* polymorphisms with pseudoexfoliation in the Chinese. *Mol Vis* **15**, 1120–6 (2009).
- Chen, L. *et al.* Evaluation of *LOXL1* polymorphisms in exfoliation syndrome in a Chinese population. *Mol Vis* **15**, 2349–57 (2009).
- Williams, S. E. *et al.* Major *LOXL1* risk allele is reversed in exfoliation glaucoma in a black South African population. *Mol Vis* **16**, 705–12 (2010).

- Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* **22**, 719–48 (1959).
- Challa, P. Genetics of pseudoexfoliation syndrome. *Curr Opin Ophthalmol* **20**, 88–91 (2009).
- Klein, R. J. *et al.* Complement factor H polymorphism in age-related macular degeneration. *Science* **308**, 385–9 (2005).
- Maller, J. *et al.* Common variation in three genes, including a noncoding variant in *CFH*, strongly influences risk of age-related macular degeneration. *Nat Genet* **38**, 1055–9 (2006).
- Chen, Y., Bedell, M. & Zhang, K. Age-related macular degeneration: genetic and environmental factors of disease. *Mol Interv* **10**, 271–81 (2010).
- Fukuda, M. TBC proteins: GAPs for mammalian small GTPase Rab? *Biosci Rep* **31**, 159–68 (2011).
- Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* **4**, 1073–81 (2009).
- Adzhubei, I. A. *et al.* A method and server for predicting damaging missense mutations. *Nat Methods* **7**, 248–9 (2010).
- de The, H. & Chen, Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. *Nat Rev Cancer* **10**, 775–83 (2010).
- Zhong, S., Salomoni, P. & Pandolfi, P. P. The transcriptional role of PML and the nuclear body. *Nat Cell Biol* **2**, E85–90 (2000).
- Nakano, M. *et al.* Common variants in *CDKN2B-AS1* associated with optic-nerve vulnerability of glaucoma identified by genome-wide association studies in Japanese. *PLoS One* **7**, e33389 (2012).
- International HapMap, C. *et al.* A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851–61 (2007).
- Nakano, M. *et al.* Three susceptible loci associated with primary open-angle glaucoma identified by genome-wide association study in a Japanese population. *Proc Natl Acad Sci U S A* **106**, 12838–42 (2009).
- Ueta, M. *et al.* Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. *J Allergy Clin Immunol* **126**, 1218–25 e10 (2010).

## Acknowledgments

The authors wish to thank all the patients and volunteers who enrolled in the study. We also thank Professor T. Miki for managing the anonymous code-assignment process; S. Ohashi, M. Yamashita, and N. Saito for processing blood samples and performing genotyping; H. Yamada for the assistance in clinical information analysis; F. Sato for the management of genotype data and building the analyzing system; T. Ichikawa for excellent secretarial assistance; and J. Bush for reviewing the manuscript. This work was supported by the grants from the Takeda Science Foundation to MN, the Collaborative Development of Innovative Seeds of Japan Science and Technology Agency (JST) to MK and KT, the Ministry of Health, Labor and Welfare of Japan to MN, KM, SK and KT, and Santen Pharmaceutical Co. Ltd. to SK and KT.

## Author contributions

Designed the research: M.K., S.K. and K.T. Performed the research: M.N., Y.I., M.U., K.I., M.F., N.O., H.A. and K.M. Analyzed the data: M.N., Y.T., R.S. and M.F. Wrote the paper: M.N., Y.I., Y.T., K.M., S.K. and K.T. All authors reviewed the manuscript.

## Additional information

**Supplementary information** accompanies this paper at <http://www.nature.com/scientificreports>

**Competing financial interests:** This study has been completed under the Collaborative Research Agreement executed by Kyoto Prefectural University of Medicine and Santen Pharmaceutical Co., Ltd. All materials and information produced throughout this study are parts of co-owned intellectual properties. The authors MF and MK are employees of Santen Pharmaceutical Co., Ltd. All the other authors declare that no conflict of interest exists.

**How to cite this article:** Nakano, M. *et al.* Novel common variants and susceptible haplotype for exfoliation glaucoma specific to Asian population. *Sci. Rep.* **4**, 5340; DOI:10.1038/srep05340 (2014).



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>